SCHEMBL18619475

SCHEMBL18619475

COc1ccc(CCNC(=O)c2cc(O)ccc2O)cc1OC

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DNMT3A Q9Y6K1 1/20 0.60
GAA P10253 1/20 0.59
CA1 P00915 3/20 0.59
CA2 P00918 3/20 0.59
CA9 Q16790 2/20 0.59
CA12 O43570 1/20 0.59
CA7 P43166 1/20 0.58
CA14 Q9ULX7 1/20 0.58
NAMPT P43490 2/20 0.57
LMNA P02545 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.56
ALDH1A1 P00352 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
SYK P43405 1/20 0.56
MAPT P10636 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29561675 0.85 ALOX5 (0.58) DNMT3ASYK
SCHEMBL898238 0.85 ALOX5 (0.58) DNMT3ASYK
SCHEMBL5071230 0.85 THRA (0.57) DNMT3AGAALMNAALDH1A1SYK
SCHEMBL4488518 0.83 GAA (0.79) GAACA1CA2CA9CA12
SCHEMBL15329262 0.81 ESRRG (0.60) LMNACYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL6267575 0.81 CYP1A2 (0.65) GAACA1CA2CA9CA12
SCHEMBL23351382 0.80 GAA (0.69) GAACA1CA2CA9CA12
SCHEMBL1812144 0.79 MEN1 (0.65) GAACA1CA2CA9CA12
SCHEMBL9809660 0.78 OPRM1 (0.54) NAMPTLMNAALDH1A1CYP1A2CYP3A4
SCHEMBL28475160 0.78 NAMPT (0.63) GAACA1CA2CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10730886-B2 Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-08-04 US claimed
US-20180251472-A1 Compound Having Effect Of Inhibiting Platelet Aggregation And Salt Thereof, And Composition For Preventing Or Treating Thrombotic Diseases, Containing Same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2018-09-06 US claimed
EP-3345910-A1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME Shin Poong Pharmaceutical Co., Ltd. (KR) 2018-07-11 EP claimed
EP-3345910-B1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2023-11-01 EP disclosed
EP-3345910-B1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2023-11-01 EP disclosed
CN-108602837-B Compound having platelet aggregation inhibitory effect, salt thereof, and composition for preventing or treating thrombotic diseases comprising same 新丰制药株式会社 2022-02-11 CN disclosed
US-10730886-B2 Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-08-04 US disclosed
US-10730886-B2 Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-08-04 US disclosed
US-20180251472-A1 Compound Having Effect Of Inhibiting Platelet Aggregation And Salt Thereof, And Composition For Preventing Or Treating Thrombotic Diseases, Containing Same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2018-09-06 US disclosed
EP-3345910-A1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME Shin Poong Pharmaceutical Co., Ltd. (KR) 2018-07-11 EP disclosed
EP-3345910-A1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME Shin Poong Pharmaceutical Co., Ltd. (KR) 2018-07-11 EP disclosed
WO-2017039395-A1 COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME 신풍제약 주식회사 2017-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180251472-A1 Compound Having Effect Of Inhibiting Platelet Aggregation And Salt Thereof, And Composition For Preventing Or Treating Thrombotic Diseases, Containing Same PLA2G7, JAK2, PF4 DNMT3A 4535/4885GAA 2276/4885CA1 3819/4885
US-10730886-B2 Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same PLA2G7, JAK2, PF4 DNMT3A 4535/4885GAA 2276/4885CA1 3819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.